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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effectiveness and safety of PCSK9 inhibitors in the primary prevention of IHD in people with HeFH.
B A C K G R O U N D
Description of the condition
Familial hypercholesterolaemia (FH) is an inheritedmetabolic dis-
ease characterised by an elevated low density lipoprotein choles-
terol (LDL-C). Historically it has been shown that, if untreated,
FH will lead to at least 50% men under 50 years of age and 30%
of women under 60 years of age to develop ischaemic heart disease
(IHD) (Slack 1969; Stone 1974). A more recent observational
study showed a potential six-fold increase in the risk of IHD in
people with the causative FHmutation compared to those without
the mutation but with similar cholesterol levels; and a 22-fold risk
compared to those with normocholesterolaemia (Khera 2016).
FH is an autosomal dominant disorder with the severe homozy-
gous form occurring in 1 in a million and the less severe heterozy-
gous FH (HeFH) in 1 in 200 to 500 (Nordestgaard 2013). Mu-
tations causing HeFH occur most commonly in the LDLR (low
density lipoprotein receptor) gene, followed by APOB (apolipot-
protein B) mutations and less commonly in the PCSK9 (propro-
tein convertase subtilisin/kexin type 9) gene (Rader 2003). These
mutations cause FH by either affecting LDL uptake in the case of
LDLR, APOB mutations or by increasing LDL receptor degrada-
tion in the case ofPCSK9which leads to an increase in LDL choles-
terol due to decreased hepatic clearance. The diagnosis of FH is
based on either clinical criteria or genetic testing (Ryan 2015).
Current registry data has shown that early diagnosis and treatment
reduces the risk of early onset IHD (Mundal 2014; Versmissen
2008). Current methods of risk assessment and treatment used
in clinical guidance are mainly adopted from non-FH (Besseling
2014; Nordestgaard 2013; Wong 2016).
Description of the intervention
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A number of approaches to inhibition of PCSK9 have been ex-
plored in both animal models and in humans (Mullard 2017).
These include inhibition at the messenger ribonucleic acid
(mRNA) level, small molecule inhibitors and monoclonal anti-
bodies directed against PCSK9. To date the monoclonal antibod-
ies have been the most evaluated. They act by binding to PCSK9
in the extracellular space and preventing the binding of PCSK9 to
the LDLR complex. This prevents LDLR degradation, which in
turn remains on the liver surface available to remove LDL-C from
the bloodstream.
As the monoclonal antibodies are relatively new to the market,
approval by regulation bodies has only recently been obtained for
both evolocumab and alirocumab (Natarajan 2016). Evolocumab
is administered at a dose of 140 mg every two weeks or 420 mg
once per month and alirocumab at either 75 mg or 150 mg every
two weeks. While the difference in LDL reduction between the
agents is minimal, both demonstrate a 59% reduction in LDL-C
when compared with placebo.
Alirocumab
Alirocumab is a human monoclonal antibody (IgG1 isotype) that
targets PCSK9 and after subcutaneous administration bioavail-
ability is estimated to be 85% with serum levels peaking at day
three to day seven post administration. At low doses, elimination
is mainly via binding to PCSK9; and at higher doses, it is largely
unsaturable via the proteolytic pathway. Its pharmacokinetics are
not influenced by age, body weight, gender, race, creatinine clear-
ance or hepatic function. The drug half-life is estimated to be 17
to 20 days, reduced to 12 days in the presence of a statin; however,
it is not felt to impact efficacy and also has no effect on statin lev-
els. Adverse effects compared with placebo include injection site
reactions, however, most are similar to placebo (EMA 2015a).
Evolocumab
Evolocumab is a human monoclonal IgG2 antibody that tar-
gets PCSK9 with maximum suppression of circulating unbound
PCSK9 achieved within four hours. After subcutaneous admin-
istration, bioavailability was 72% with median peak serum levels
occurring after three to four days. Like alirocumab, the effects of
body parameters, including creatinine clearance and hepatic func-
tion, have not been found to impact on drug pharmacokinetics.
The adverse event profile is similar to placebo, apart from an in-
crease in 3% of upper respiratory tract infection. Evolocumab has
a half life of 11 to 17 days and there is an approximate 20% re-
duction in serum levels with concomitant use of high-dose statins,
which does not appear to influence efficacy (EMA 2015b).
In people with HeFH on high-dose statins, the systemic expo-
sure of evolocumab was slightly lower than in individuals on a
low-to-moderate dose of statins (the ratio of AUClast 0.74 (90%
confidence interval (CI) 0.29 to 1.90)). An approximately 20%
increase in the clearance is in part mediated by statins increas-
ing the concentration of PCSK9 which does not adversely impact
the pharmacodynamic effect of evolocumab on lipids. Population
pharmacokinetic analysis indicates no appreciable differences in
evolocumab serum concentrations in people with hypercholes-
terolaemia (non-FH or FH) taking concomitant statins.
How the intervention might work
PCSK9 is an enzyme that plays a crucial role in LDL receptor
recycling by acting as a ligand for hepatic LDL receptors, target-
ing them for degradation via the endo-lysosomal pathway and
preventing their return to the cell surface (Horton 2003; Lagace
2006; Maxwell 2005). Genetic case studies have shown that gain
of function mutations can lead to HeFH, which leads to increased
expression of PCSK9, which in turn leads to increased degradation
of the LDLR, resulting in decreased LDL clearance and higher
LDL cholesterol (Abifadel 2003; Rader 2003). However, other ge-
netic cohort studies associated with loss of function and decreased
PCSK9 expression have suggested an association with very low
LDL levels and life-time risk of IHD (Cohen 2006; Rashid 2005).
The fact that decreased expression of PCSK9 effectively lowers
LDL suggests this has a potential impact as a treatment for FH,
where excess LDL burden is a key factor in the risk of IHD in
people with HeFH. In vivo the PCSK9 enzyme binds to the ex-
tracellular part of the LDLR, targeting it for degradation as de-
scribed above. Similarly PCSK9 antibody therapies bind extracel-
lularly to PCSK9 preventing it from degrading the LDL receptor
(Natarajan 2016). This in turn leads to an increased clearance of
LDL cholesterol and a decrease in LDL.
Why it is important to do this review
FH has many unmet needs in the area of diagnosis and risk stratifi-
cation, but also in treatment, with some studies showing that up to
50% of individuals failed to meet treatment targets or were not on
regular statin medication (Nordestgaard 2013; Ryan 2015). The
incidence and existence of statin intolerance has receivedmuch de-
bate and is controversial given the lack of consensus on intolerance
or statin-associated muscular symptoms (Thompson 2016). De-
pendent on the source, figures suggesting statin-associated muscle
symptoms vary from 5% to 20%, being lower in clinical trials
than in observational studies, therefore, alternative treatments are
required (Parker 2013; Zhang 2013).
Recent guidance on managing HeFH outlines that statins are
the first line of treatment, followed by ezetimibe or bile acid se-
questrants for those failing to achieve LDL targets (Nordestgaard
2013). The exact role for PCSK9 inhibitors in this pathway re-
mains to be confirmed; however, a recent consensus document
from the European Society of Cardiology (ESC) highlights the
lack of clinical endpoints from trials to date and suggests that the
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use of these drugs should be restricted to those with HeFH, those
that are at very high risk of IHD or who are unable to tolerate
statin therapy (Catapano 2016).
There are a number of previous systematic reviews on PCSK9
monoclonal antibodies that have includedHeFH (Navarese 2015;
Schmidt 2017; Zhang 2015). Some have included short-term
studies (up to 12 weeks) which are not powered to translate to clin-
ically meaningful outcomes or may lead to bias due to small num-
ber of events over a short trial duration (Navarese 2015; Zhang
2015). Furthermore, in all studies there has been limited consider-
ation of the underlying genetic defect on PCSK9 inhibitor effec-
tiveness and discussion regarding the benefit of incorporation into
the FH clinical pathway (Navarese 2015; Schmidt 2017; Zhang
2015). This systematic review will include people with FH of all
ages.
By not limiting the search to one particular method of PCSK9
inhibition, this review will act as a resource for comparing ef-
fectiveness as well as the side effect profile for clinicians manag-
ing people with FH. However, within each drug class, this review
will consider outcomes based on the individual drugs (rather than
combining these studies and analysing a drug class as a whole).
This approach is of particular importance given that recent clinical
trials of PCSK9 inhibitors have highlighted that even within the
same class of drug, there are important differences in side effects
and efficacy (Ridker 2017; Sabatine 2017).
In summary, a systematic reviewwill assist with assessing the utility
of PCSK9 inhibitors in people with HeFH.
O B J E C T I V E S
To assess the effectiveness and safety of PCSK9 inhibitors in the
primary prevention of IHD in people with HeFH.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled clinical trials (RCTs).
Types of participants
All ages with either a genetically proven or a clinical diagnosis of
HeFH. Clinical diagnosis will be based on recognised diagnostic
criteria, e.g. Simon Broome or the Dutch lipid clinic network
criteria (Ryan 2015).
Types of interventions
PCSK9 inhibitors given alone versus those given with usual care
or versus placebo. Usual care may consist of statin or ezetimibe
therapy.
RCTs of at least one year in duration with a minimum follow-up
of six months (Taylor 2013). This time point was selected in order
to provide safety data and longer-term outcome data that would
enhance current care of people with FH.
Types of outcome measures
The ultimate goal of treatment with PCSK9 inhibitors is to re-
duce the incidence of and mortality from cardiovascular diseases.
However, as these drugs are new to the market, RCTs may not yet
report such outcome data. Therefore, where mortality data are not
available, we will use lipid parameters as surrogate end points for
assessing effectiveness. The ’change’ means the difference between
the values at the beginning and at the end of follow-up. Where
possible, we will report the means of both absolute (mmol/L) and
relative (%) changes in lipids between groups. An appropriate ref-
erenced and validated definition will be used for each of the pri-
mary and secondary outcomes where available.
Primary outcomes
1. The composite end-point of IHD (defined as urgent
coronary revascularization, unstable angina pectoris, non-fatal
and fatal myocardial infarction (as defined by the third universal
definition of myocardial infarction (Thygesen 2012)) and
coronary heart disease (CHD) death)*
2. Lipid parameters (total cholesterol, LDL-C, HDL-C,
triglycerides (mmol/L), apolipoprotein A1 (g/L), apolipoprotein
B (g/L) and lipoprotein[a] (mg/dL))
Secondary outcomes
1. Any adverse events (including type 2 diabetes and cancer)
2. All-cause mortality
3. Cognitive function
4. Fasting glucose (mmol/L) and HbA1c (mmol/mol)
5. Myopathy or creatinine kinase rise (units/L)
6. Growth and pubertal development (e.g. z scores or centiles)
* It is anticipated that such outcomes will not be available for those
under 18 years of age.
Search methods for identification of studies
We will search for all relevant published and unpublished trials
without restrictions on language, year or publication status.
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Electronic searches
We will identify relevant studies from the Group’s Inborn Errors
of Metabolism Trials Register using the terms: (hypercholestero-
laemia OR hypercholesterolemia) AND (PCSK* OR proprotein
OR evolocumab OR alirocumab OR IgG1 OR IgG2 OR anti-
bod*).
The Inborn Errors of Metabolism Trials Register is compiled from
electronic searches of the Cochrane Central Register of Controlled
Trials (CENTRAL) (updated with each new issue of the Cochrane
Library), weekly searches of MEDLINE. Unpublished work is
identified by searching through the abstract books of the Society
for the Study of Inborn Errors of Metabolism conference and the
SHS (Scientific Hospital Supplies) Inborn Error Review Series.
For full details of all searching activities for the register, please see
the relevant section of the Cochrane Cystic Fibrosis and Genetic
Disorders Group’s website.
Wewill also search the followingdatabases, registries and resources:
• Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library
www.thecochranelibrary.com;
• Medline Ovid (1946 to present);
• Web of Science (1898 to present);
• US National Institutes of Health Ongoing Trials Register
Clinicaltrials.gov (www.clinicaltrials.gov);
• World Health Organization International Clinical Trials
Registry Platform (WHO ICTRP) (apps.who.int/trialsearch).
For full search strategies, please see the appendices (Appendix 1).
Searching other resources
We will check the bibliographies of included studies and any rele-
vant systematic reviews identified for further references to relevant
trials.
Data collection and analysis
Selection of studies
Two authors (AR and SN) will independently review the titles
and abstracts of articles found in the electronic searches for po-
tential eligible studies for review. The same two authors will in-
dependently assess full manuscripts against the inclusion criteria
and where necessary resolve any disagreements with discussion or
involvement of third author (PC).
Data extraction and management
Two authors (AR and SN) will independently extract relevant
primary and secondary outcome data, with disagreement resolved
either by discussion or by the involvement of a third author (PC).
(See Appendix 2 for the data extraction form.)
Assessment of risk of bias in included studies
Two authors (AR and SN) will independently assess risk of bias,
with disagreement resolved either by discussion or by the involve-
ment of a third author (PC). We will assess risk of bias of individ-
ual RCTs using the Cochrane ’Risk of bias’ assessment tool based
on the following items.
• Random sequence generation
• Allocation concealment
• Blinding
• Missing outcome data
• Selective reporting
• Other biases
We will grade the individual items at ’low’, ’unclear’, or ’high’ risk
of bias (Higgins 2011c).
Measures of treatment effect
For binary outcome measures (such as adverse events), we will
calculate a pooled estimate of the treatment effect for each outcome
across trials using the risk ratio (RR) and 95% confidence intervals
(CIs) where appropriate. If multiple adverse events are reported in
the included trials, we will use 99% CIs to account for multiple
statistical testing (Higgins 2011d).
For continuous outcomes (such as lipid parameters and cognitive
function), we will record either the mean relative change from
baseline for each group or the mean post-treatment or post-inter-
vention values and the standard deviation (SD). If the papers re-
port standard errors (SE) (and if it is possible) we will convert these
to SDs. We will present a pooled estimate of treatment effect by
calculating the mean difference (MD) and 95%CIs. If we become
aware that some data are skewed and therefore we are not able
to enter and analyse these within the Review Manager (RevMan)
software, we will report these narratively (RevMan 2014). Where
data are presented according to different scales (e.g. cognitive func-
tions), we will present the standardised mean difference (SMD)
and 95% CIs.
For any time-to-event outcomes included in the review (such as
all cause mortality), we plan to extract the log hazard ratio (HR)
and SE estimates from the trials and we aim to combine all results
using the generic inverse variance method. If log HRs are not
available, we will extract log rank P value estimates or survival
curve estimates to convert into log HRs and SEs as detailed in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011b).
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Unit of analysis issues
Cross-over trials or clustered randomised trials are not appropriate
designs and we will not evaluate these in this review.
If eligible trials have more than one intervention or control arm
(e.g. two different PCSK9 inhibitors compared to a control treat-
ment), we will make separate comparisons of each PCSK9 in-
hibitor invention compared to each control to avoid duplication
of participants in the analysis.
Dealing with missing data
Where possible, we will report the numbers and reasons for drop-
outs and withdrawals in all intervention groups. We will also state
whether the papers specify if there were any dropouts or with-
drawals. We will contact authors for clarification on missing in-
formation, where possible.
In order to allow an intention-to-treat analysis, we will seek data
on the number of participants within each outcome event, by
allocated treated group, irrespective of compliance and whether
or not the individual is later thought to be ineligible or otherwise
excluded from treatment or follow-up.
We have chosen not to include cross-over trials due to the risk
of treatment carry-over effect, particularly on the LDL receptor.
Cluster RCTs will not be appropriate given the variability in FH
participants.
Assessment of heterogeneity
We will assess between-trial clinical heterogeneity by examining
differences in design, participant characteristics, direction of treat-
ment effect and overlap of treatment effect CIs on forest plots.
We will assess between-trial statistical heterogeneity using the I²
statistic and Tau², the latter calculated from random-effects meta-
analysis.
We will interpret an I² statistic greater than 50% as an indica-
tion of important heterogeneity. Where important heterogene-
ity is present between studies, we will perform random-effects
meta-analysis and we will explore potential sources of hetero-
geneity through subgroup analysis (see Subgroup analysis and
investigation of heterogeneity).
Where very high levels of between-trial heterogeneity are present
for any outcome (I² statistic greater than 75%) which cannot be
readily explained, we will not not undertake anymeta-analyses but
will perform a narrative review.
Assessment of reporting biases
If we are able to include a sufficient number of trials, i.e. 10 or
more as recommended by the Cochrane Handbook of Systematic
Reviews of Interventions (Higgins 2011a), we will attempt to assess
whether our review is subject to publication bias by using a funnel
plot. If we detect asymmetry, we will explore causes other than
publication bias.
Data synthesis
If we identify important levels of heterogeneity (as defined above),
we will present pooled estimates of the treatment effect using a
random-effects model. If this level of heterogeneity is not identi-
fied, we will compute pooled estimates of the treatment effect for
each outcome under a fixed-effect model.
Subgroup analysis and investigation of heterogeneity
We will determine the consistency of PCSK9 inhibitor effect on
major cardiovascular events for the following subgroups:
• gender;
• age (younger than 18 years of age or 18 years and over);
• diabetes at baseline; as defined by American Diabetes
Association criteria for diabetes mellitus diagnosis (American
Diabetes Association 2015);
• baseline LDL-C level (continuous and above 2.5 mmol/L);
• genotype of underlying mutation for HeFH.
We will employ meta-regression (weighted for the inverse variance
weights (Thompson 2002)) to explore whether treatment effects
differed between trial baseline characteristics on a continuous scale
if we are able to include a sufficient number of trials and such an
analysis is deemed appropriate.
Sensitivity analysis
To assess the validity and robustness of the review’s results, we will
perform sensitivity analyses excluding trials at high risk of bias for
one or more domains and compare the direction and magnitude
of the results of each sensitivity analysis to that of the relevant
primary analysis.
Summary of findings and quality of the evidence
(GRADE)
We will present a summary of findings table for each comparison
made in the review. The following outcomes will be reported in
all tables (chosen based on relevance to clinicians and consumers):
CVD (composite endpoint); lipid parameters; adverse events; all-
cause mortality; cognitive function; genotype of underlying mu-
tation for HeFH.
We will determine the quality of the evidence using the GRADE
approach; and downgrade evidence in the presence of a high risk
of bias in at least one trial, indirectness of the evidence, unex-
plained heterogeneity or inconsistency, imprecision of results or
high probability of publication bias. We will downgrade by one
level if considered serious and by two levels if very serious.
We will present results in the Summary of Findings tables in the
most appropriate way for the data available, e.g. if included trials
report multiple adverse events, we will make a general statement
regarding all reported adverse events rather than considering each
event separately for brevity and clarity in the tables.
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A P P E N D I C E S
Appendix 1. Search methods - electronic searches
Database/ Resource Strategy
Cochrane Central Register of Controlled Trials (CENTRAL) [Search Manager Form]
#1MeSH descriptor: [Hyperlipoproteinemia Type II] this term only
#2 (familial or inherited) near/2 (hypercholesterol*mia*)
#3 (Hyperlipoprotein*mia*) near/2 (type II or type IIa or type IIb
or type 2 or type 2a or type 2b)
#4 #1 or #2 or #3
#5 PCSK-9 or PCSK9
#6 MeSH descriptor: [Proprotein Convertase 9] this term only
#7 IgG1
#8 Alirocumab
#9 IgG2
#10 Evolocumab
#11 MeSH descriptor: [Antibodies, Monoclonal] this term only
#12 kexin type 9
#13 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12
#14 #4 and #13
MEDLINE Ovid (1946 onwards) 1 ((familial or inherited) adj2 hypercholesterol?emia$).tw.
2. Hyperlipoproteinemia Type II/
3. (Hyperlipoprotein?emia$ adj (type II or type IIa or type IIb or
type 2 or type 2a or type 2b)).tw.
4. 1 or 2 or 3
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(Continued)
5. PCSK-9.tw.
6. PCSK9.tw.
7. Proprotein Convertase 9/
8. IgG1.tw.
9. Alirocumab.tw.
10. IgG2.tw.
11. Evolocumab.tw.
12. Antibodies, Monoclonal/
13. kexin type 9.tw.
14. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13
15. 4 and 14
16. randomized controlled trial.pt.
17. controlled clinical trial.pt.
18. randomized.ab.
19. placebo.ab.
20. drug therapy.fs.
21. randomly.ab.
22. trial.ab.
23. groups.ab.
24. 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25. (animals not (humans and animals)).sh.
26. 24 not 25
27. 15 and 26
NOTE: Lines#16- #26 are the Cochrane Highly Sensitive Search
Strategy for identifying randomized trials in MEDLINE: sensitivity-
maximizing version (2008 revision); Ovid format
Web of Science (1898 to present) #1 TS=((familial or inherited) NEAR/2 hypercholesterol*emia*)
#2 TS=Hyperlipoprotein*emia*
#3 TS=(type II OR type IIa OR type IIb OR type 2 OR type 2a OR
type 2b)
#4 #3 AND #2
#5 #4 OR #1
#6 TS=(PCSK-9 ORPCSK9OR Proprotein Convertase 9OR IgG1
OR Alirocumab OR IgG2 OR Evolocumab OR antibody OR an-
tibiodies OR kexin type 9)
#7 #6 AND #5
#8 TS= clinical trial* OR TS=research design OR TS=comparative
stud* ORTS=evaluation stud* ORTS=controlled trial* OR TS=fol-
low-up stud* OR TS=prospective stud* OR TS=random* OR TS=
placebo* OR TS=(single blind*) OR TS=(double blind*) OR TS=
(triple blind*) OR TS=(treble blind*) or TS=(singleblind*) OR TS=
(doubleblind*) OR TS=(tripleblind*) OR TS=(trebleblind*) OR
TS=blinded OR TS=cross* OR TS=RCT
#9 #8 AND #7
Note: Line #8 is based on a filter fromUniversity of Alberta Libraries
http://guides.library.ualberta.ca/c.php?g=248586&p=1655962 (ac-
cessed 05 Oct 2017)
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(Continued)
ClinicalTrials.gov [Advanced Search Form]
OTHER TERMS: PCSK9 OR PCSK-9 OR proprotein OR
evolocumab OR alirocumab OR IgG1 OR IgG2 OR antibody OR
antibodies OR kexin
STUDY TYPE: Interventional Studies
CONDITION/DISEASE: hypercholesterolaemiaORhypercholes-
terolemia OR hyperlipoproteinemia OR hyperlipoproteinaemia
WHO ICTRP [Advanced Search Form]
CONDITION: hypercholesterolaemia OR hypercholesterolemia
OR hyperlipoproteinemia OR hyperlipoproteinaemia [AND]
INTERVENTION: PCSK9 OR PCSK-9 OR proprotein OR
evolocumab OR alirocumab OR IgG1 OR IgG2 OR antibody OR
antibodies OR kexin
RECRUITMENT STATUS: All
Appendix 2. Data extraction form
Study selection, quality assessment & data extraction form
First author Journal/Conference
Proceedings, etc.
Year
Study eligibility
RCT/Quasi/CCT Relevant participants Relevant interventions Relevant outcomes
Yes / No /Unclear Yes / No / Unclear Yes / No / Unclear Yes / No / Unclear
Do not proceed if any of the above answers are ‘No’. If study to be included in ‘Excluded studies’
section of the review, record below the information to be inserted into ‘Table of excluded studies’.
Participants and trial characteristics
Participant characteristics
Further details
Age (mean, median, range, etc.)
Sex of participants (numbers / %, etc.)
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(Continued)
Disease status / type, etc. (if applicable)
Other
Risk of bias
Allocation of intervention
State here method used to generate allocation and reasons for
grading
Risk of bias (circle)
Low (Random)
High (e.g. alternate)
Unclear
Concealment of allocation
State here method used to conceal allocation and reasons for grad-
ing
Risk of bias (circle)
Low
High
Unclear
Blinding
Person responsible for participants care Yes / No
Participant Yes / No
Outcome assessor Yes / No
Other (please specify) Yes / No
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Intention-to-treat
All participants entering trial
15% or fewer excluded
More than 15% excluded
Not analysed as ‘intention-to-treat’
Unclear
Were withdrawals described? Yes/ No/ not clear
Discuss if appropriate……………………………………………………………………………………
………………………………………………………………………………………………….
Selective outcome reporting
Have you been able to access the trial protocol?
Are all outcomes listed in protocol reported in
the full trial paper?
Data extraction
Outcomes relevant to your review
Reported in paper (circle)
Outcome 1 Composite CVD Yes / No
Outcome 2 Lipid parameters Yes / No
Outcome 3 Any adverse events Yes / No
Outcome 4 All cause mortality Yes / No
Outcome 5 Cognitive function Yes / No
Outcome 6 Fasting glucose Yes / No
Outcome 7 Myopathy / creatinine kinase rise Yes / No
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(Continued)
Outcome 8 Genotype Yes / No
For continuous data
Code
Of
paper
Outcomes (re-
name)
Unit of
measurement
Intervention group Control group Details if outcome
only described in
text or other data
presented,
e.g. P value.
n Mean (SD) n Mean (SD)
For dichotomous data
Code of
Paper
Outcomes (rename) Intervention group (n) Control group (n)
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(Continued)
Other information which you feel is relevant to the results
Indicate if: any data were obtained from the primary author if results were estimated from graphs
etc. or calculated by you using a formula (this should be stated and the formula given). In general if
results not reported in paper(s) are obtained this should be made clear here to be cited in review
Trial characteristics
Further details
Single centre / multicentre
Country / countries
How was participant eligibility defined?
How many people were randomised?
Number of participants in each intervention group
Number of participants who received intended treatment
Number of participants who were analysed
Drug treatment(s) used
Dose / frequency of administration
Duration of treatment (State weeks / months, etc., if cross-over
trial give length of time in each arm)
Median (range) length of follow-up reported in
this paper (state weeks, months or years or if not stated)
Timepoints when measurements were taken during the study
Timepoints reported in the study
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(Continued)
Timepoints you are using in metaview
Trial design (e.g. parallel / cross-over*)
Other
C O N T R I B U T I O N S O F A U T H O R S
AR drafted the protocol with input from the remaining authors.
D E C L A R A T I O N S O F I N T E R E S T
All authors: none known.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research, UK.
This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the
Cochrane Cystic Fibrosis and Genetic Disorders Group.
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